臨床外科75巻3号

2020年03月発行

特集 一般・消化器外科医のための　できる！ 漢方 がん化学療法完遂のための漢方

末梢神経障害

著者： 進藤吉明¹

所属機関： ¹中通総合病院消化器センター消化器外科

ページ範囲：P.318 - P.321

【ポイント】
◆CIPNの機序は未解明の点が多いうえ，評価法も主観的なものが多く，客観的に評価できるものが少ない．
◆CIPN出現時には，原因薬剤の投与延期，減量，またStop ＆ Goなどが重要である．
◆CIPNに対する漢方薬の効果はエビデンスが少なく，積極的な使用は推奨しないが，試用は許容される．

参考文献

1）田村和夫：「支持療法の進歩：副作用・合併症対策」末梢神経障害．Mebio Oncol 2：51-58，2005

2）河野　豊，永田博司：「薬物と神経筋障害　診断と治療の進歩」薬物による神経障害 末梢神経障害の機序．日内会誌96：1585-1590，2007

3）Gauchan P, Andoh T, Kato A, et al：Effects of the prostaglandin E1 analog limaprost on mechanical allodynia caused by chemotherapeutic agents in mice. J. Pharmacol Sci 109：462-472, 2009

4）Mielke S, Sparreboom A, Steinberg SM, et al：Association of Paclitaxel pharmacyokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res 11：4843-4850, 2005

5）Ling B, Authier N, Balayssac D, et al：Behavioral and pharmacyological descryiption of oxaliplatin-induced painfull neuropathy in rat. Pain 128：225-234, 2007

6）Adelsberger H, Quasthoff S, Grosskreutz J, et al：The chemotherapeutic oxaliplatin alters voltage-gated Na（＋）channel kinetics on rat sensory neurons. Eur J Pharmacol. 406：25-32, 2000

7）Sandkühler J：Learning and memory in pain pathway. Pain 88：113-118, 2000

8）Brooks J, Tracey I：From nociception to pain perception：imaging the spinal and supraspinal pathways. J Anat 207：19-33, 2005

9）National Cancer Institute：Common Terminology Criteria for Adverse Event（NCI-CTCAE）　http://ctep.cancer.gov/

10）Functional Assessment of Chronic Illness Therapy（FAC-IT）　http://www.facit.org/

11）Tournigand C, Cernantes A, Figar A, et al：OPTIMOXa：A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a Stop-and-Go fashion in advanced colorectal cancer-A GERCOR study. J. Clin Oncol 24：394-400, 2006

12）Grothey A, Hari LL, Rowland KM, et al：Intermittent oxaliplatin（oxali）administration and time-to-treatment failure（TTF）in metastatic colorectal cancer（mCRC）：final results of the phase Ⅲ CONcePT trial. J Clin Oncol 26（Suppl）：4010, 2008

13）Ushio S, Egashira N, Sada H, et al：Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. Eur J Cancer 48：1407-1413, 2012

14）Bahar MA, Andoh T, Ogura K, et al：Herbal medicine Goshajinkigan prevents paclitaxel-induced mechanical allodynia without impairing antitumor activity of paclitaxel. Evid Based Complement Alternat Med 2013：849754, 2013

15）Mizuno K, Kono T, Suzuki Y, et al：Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat. J Pharmacol Sci 125：91-98, 2014

16）Matsumura Y, Yokoyama Y, Hirakawa H, et al：The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action. Mol Pain 10：61, 2014

17）Kato Y, Tateai Y, Ohkubo M, et al：Gosha-jinki-gan reduced oxaliplatin-induced hypersensitivity to cold sensation and its effect would be related to suppression of the expression of TRPM8 and TRPA1 in rats. Anti-Cancer Drugs 25：39-43, 2014

18）Nishioka M, Shimada M, Kurita N, et al：The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 16：322-327, 2011

19）Kaku H, Kumagai S, Onoue H, et al：Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy：A multicenter collaborative study. Exp Ther Med 3：60-65, 2012

20）Kono T, Hata T, Morita S, et al：Goshajinkigan oxaliplatin neurotoxicity evaluation（GONE）：a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy. Cancer Chemother Pharmacol 72：1283-1290, 2013

21）Abe H, Kawai Y, Mori T, et al：The Kampo medicine Goshajinkigan prevents neuropathy in breast cancer patients treated with docetaxel. Asian Pac J Cancer Prev 14：6351-6356, 2013

22）Oki E, Emi Y, Kojima H, et al：Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy（GENIUS trial）：a placebo-controlled, double-blind, randomized phase Ⅲ study. Int J Clin Oncol 20：767-775, 2015

23）進藤吉明，天満和男，今野広志，他：牛車腎気丸によるOxaliplatin関連末梢神経障害の軽減効果についての検討．癌と化療35：863-865，2008

24）進藤吉明：【神経障害性疼痛へのアプローチ】がん化学療法に伴う末梢神経障害に対する牛車腎気丸＋ブシ末の効果．漢方医学37：95-98，2013

25）河野　透：がん薬物療法の副作用に対する漢方薬の考え方と使いかた 末梢神経障害．薬局69：47-52，2018

26）Nakae H, Fujita Y, Igarashi T, et al：Serum aconitine concentrations after taking powdered processed Aconiti tuber. Biomed Res 29：225-231, 2008

27）小泉修一，柴田圭輔：特集整形外科漢方処方マニュアル〈基礎〉　ブシ；神経障害性疼痛．MB Orthop 28：1-7，2015

28）小泉修一：附子による慢性疼痛のグリア性制御メカニズム．ペインクリニック40：907-915，2019